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It could be argued that gene therapy is the ultimate perso-
nalised medicine and potentially preventive medicine too.
There is little closer to the personalisation of medicine
than the ability to repair or restore the function of a per-
son’s own faulty genes, the core principle of gene therapy.
With the first approval of gene therapy products in both
the western and eastern world, this is increasingly close to
becoming a reality in clinical practice. At the same time,
the advances in scientific understanding and technological
ability to analyse the human genome imply that gene ther-
apy could also be used to prevent the development of
disease.
Many rare diseases are monogenic diseases and as
such are ideal candidates for gene therapy. One example
is Acute Intermittent Porphyria (AIP). The disease is
caused by mutations in the porphobilinogen deaminase
(pbgd) gene which encodes one of the enzymes involved
in the haem biosynthesis pathway. This gives rise to
enzyme deficiency and in turn accumulation of inter-
mediate toxic metabolites in the heam pathway. The dis-
ease which has prevalence in Europe of approximately
5.9 per million population, manifests as severe abdom-
inal pain, mental symptoms and peripheral neuropathy
leading to poor life quality. Current therapy targets the
symptoms of the disease without being able to modify
the pathology, let alone provide a cure. AMT-021 is an
adeno-associate virus 5 (AAV5)-based gene therapy pro-
duct that aims to specifically deliver and express PBGD
in the liver cells of affected patients therefore restoring
the defect in haem biosynthesis and avoiding the accu-
mulation of associated toxic metabolites. Following a
series of preclinical development programme and pivotal
toxicology and safety studies AMT-021 entered clinical
trials (Phase I) in December 2012. This was the first
time a potentially curative treatment was tested in AIP
patients and from a scientific perspective this was the
first time an AAV-5 based gene therapy product was
administered in humans. The trial is expected to be
completed in the second half of 2014.
Outside the significance of this drug development pro-
gramme for the treatment of patients with AIP and gene
therapy for rare diseases, it also represents a successful
example of an academic-industrial partnership that has
been made possible by funding from the European Com-
mission’s Framework Programme 7. The AIPGENE con-
sortium right from the beginning aimed to harness
excellent pre-clinical research and by following a very prag-
matic and translational approach focused it on developing
a much needed therapy for a rare disease while extending
the scientific frontiers of gene therapy as well.
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